1. Home
  2. EQ vs NSYS Comparison

EQ vs NSYS Comparison

Compare EQ & NSYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • NSYS
  • Stock Information
  • Founded
  • EQ 2017
  • NSYS 1981
  • Country
  • EQ United States
  • NSYS United States
  • Employees
  • EQ N/A
  • NSYS 775
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • NSYS Industrial Machinery/Components
  • Sector
  • EQ Health Care
  • NSYS Technology
  • Exchange
  • EQ Nasdaq
  • NSYS Nasdaq
  • Market Cap
  • EQ 24.8M
  • NSYS 28.6M
  • IPO Year
  • EQ 2018
  • NSYS N/A
  • Fundamental
  • Price
  • EQ $0.74
  • NSYS $10.37
  • Analyst Decision
  • EQ Buy
  • NSYS
  • Analyst Count
  • EQ 2
  • NSYS 0
  • Target Price
  • EQ $5.00
  • NSYS N/A
  • AVG Volume (30 Days)
  • EQ 304.3K
  • NSYS 5.2K
  • Earning Date
  • EQ 11-13-2024
  • NSYS 11-07-2024
  • Dividend Yield
  • EQ N/A
  • NSYS N/A
  • EPS Growth
  • EQ N/A
  • NSYS 109.80
  • EPS
  • EQ N/A
  • NSYS 1.55
  • Revenue
  • EQ $45,914,000.00
  • NSYS $135,567,000.00
  • Revenue This Year
  • EQ N/A
  • NSYS N/A
  • Revenue Next Year
  • EQ N/A
  • NSYS N/A
  • P/E Ratio
  • EQ N/A
  • NSYS $6.51
  • Revenue Growth
  • EQ 7.70
  • NSYS N/A
  • 52 Week Low
  • EQ $0.48
  • NSYS $8.60
  • 52 Week High
  • EQ $3.25
  • NSYS $19.15
  • Technical
  • Relative Strength Index (RSI)
  • EQ 40.86
  • NSYS 41.91
  • Support Level
  • EQ $0.66
  • NSYS $9.53
  • Resistance Level
  • EQ $0.77
  • NSYS $10.51
  • Average True Range (ATR)
  • EQ 0.08
  • NSYS 0.55
  • MACD
  • EQ -0.01
  • NSYS -0.02
  • Stochastic Oscillator
  • EQ 26.09
  • NSYS 37.00

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

About NSYS Nortech Systems Incorporated

Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical and manufacturing services and support including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense and Industrial markets with key revenue coming from Medical device and product manufacturing and related engineering services.

Share on Social Networks: